Arbutus Biopharma Corp (NASDAQ:ABUS) – Equities researchers at William Blair issued their Q1 2017 earnings per share (EPS) estimates for shares of Arbutus Biopharma Corp in a report released on Wednesday, Zacks Investment Research reports. William Blair analyst Y. Xu expects that the biopharmaceutical company will earn ($0.25) per share for the quarter. William Blair also issued estimates for Arbutus Biopharma Corp’s Q2 2017 earnings at ($0.39) EPS, Q3 2017 earnings at ($0.39) EPS, Q4 2017 earnings at ($0.39) EPS, FY2017 earnings at ($1.42) EPS, FY2018 earnings at ($1.63) EPS and FY2019 earnings at ($1.76) EPS.
COPYRIGHT VIOLATION NOTICE: This story was reported by BBNS and is owned by of BBNS. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://baseballnewssource.com/markets/q1-2017-earnings-estimate-for-arbutus-biopharma-corp-abus-issued-by-william-blair-updated-updated/525343.html.
Other research analysts have also recently issued reports about the stock. Chardan Capital upgraded shares of Arbutus Biopharma Corp from a “neutral” rating to a “buy” rating and raised their target price for the stock from $3.00 to $6.00 in a report on Tuesday, April 4th. Bloom Burton upgraded shares of Arbutus Biopharma Corp from an “accumulate” rating to a “buy” rating in a report on Monday, January 9th. Zacks Investment Research upgraded shares of Arbutus Biopharma Corp from a “sell” rating to a “hold” rating in a report on Friday, February 17th. Finally, Wedbush reiterated an “outperform” rating and issued a $10.00 target price (up from $9.00) on shares of Arbutus Biopharma Corp in a research note on Wednesday, March 22nd. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Arbutus Biopharma Corp currently has an average rating of “Buy” and a consensus price target of $6.25.
Shares of Arbutus Biopharma Corp (NASDAQ:ABUS) traded down 0.746% on Friday, hitting $3.325. 114,235 shares of the stock were exchanged. Arbutus Biopharma Corp has a one year low of $2.35 and a one year high of $5.48. The firm’s 50 day moving average price is $3.10 and its 200 day moving average price is $2.89. The firm’s market cap is $182.95 million.
A number of hedge funds and other institutional investors have recently modified their holdings of ABUS. K2 Principal Fund L.P. increased its position in Arbutus Biopharma Corp by 69.3% in the third quarter. K2 Principal Fund L.P. now owns 107,620 shares of the biopharmaceutical company’s stock valued at $370,000 after buying an additional 44,070 shares during the period. Oxford Asset Management acquired a new position in Arbutus Biopharma Corp during the fourth quarter valued at approximately $392,000. Baker BROS. Advisors LP acquired a new position in Arbutus Biopharma Corp during the third quarter valued at approximately $621,000. Bank of Montreal Can increased its position in Arbutus Biopharma Corp by 6.3% in the third quarter. Bank of Montreal Can now owns 861,553 shares of the biopharmaceutical company’s stock valued at $2,964,000 after buying an additional 50,768 shares during the period. Finally, Armistice Capital LLC increased its position in Arbutus Biopharma Corp by 38.6% in the fourth quarter. Armistice Capital LLC now owns 1,940,000 shares of the biopharmaceutical company’s stock valued at $4,753,000 after buying an additional 540,000 shares during the period. Institutional investors and hedge funds own 61.24% of the company’s stock.
Arbutus Biopharma Corp Company Profile
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arbutus Biopharma Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corp and related companies with our FREE daily email newsletter.